Back to top
more

Travere Therapeutics (TVTX)

(Real Time Quote from BATS)

$6.68 USD

6.68
68,947

-0.14 (-2.05%)

Updated May 9, 2024 10:46 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth B Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for TVTX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Travere Therapeutics, Inc. [TVTX]

Reports for Purchase

Showing records 61 - 80 ( 126 total )

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 61

02/07/2023

Daily Note

Pages: 110

HCW 2023 Top Picks: Seize the Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 62

02/01/2023

Daily Note

Pages: 17

Biotechnology Survey Says: Nephrology Survey Checks Pulse On IgAN Market

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 63

01/27/2023

Industry Report

Pages: 10

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 64

01/23/2023

Daily Note

Pages: 36

Biotechnology- 4Q22 Commercial Biotech Preview: A New Hope

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 65

01/20/2023

Industry Report

Pages: 9

HEALTHCARE - The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 66

01/17/2023

Industry Report

Pages: 9

The Week Ahead in Life Sciences

Provider: Wedbush Securities Inc.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 67

01/10/2023

Company Report

Pages: 8

Travere Outlines 2023 Milestones; Sparsentan IgAN PDUFA on February 17 Is a Major Catalyst; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 68

01/09/2023

Company Report

Pages: 4

Provides 4Q22 Preannouncement, Outlines FY23 Goals With Sparsentan Up First

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 5.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 69

11/16/2022

Industry Report

Pages: 12

Kidney KOL Check - Entering The IgAN Era

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 70

11/08/2022

Daily Note

Pages: 11

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 71

11/03/2022

Company Report

Pages: 8

3Q Recap; Revised REMS Proposal For Sparsentan in IgAN Submitted; New PDUFA Date February 17, 2023; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 72

10/28/2022

Daily Note

Pages: 20

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 73

10/28/2022

Company Report

Pages: 8

With ASN/Kidney Week Approaching, TVTX Focuses on 2/17/23 PDUFA

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 74

10/14/2022

Daily Note

Pages: 8

MORNING CALL

Provider: Wedbush Securities Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 75

10/14/2022

Company Report

Pages: 7

Year Of The Kidney Extended To 2023 As Sparsentan PDUFA Shifts Out on REMS Add

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 76

10/14/2022

Company Report

Pages: 9

Sparsentan PDUFA Delayed; Reducing PT to $36 on More Gradual Uptake and Potential Liver Tox Risk

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 77

10/13/2022

Daily Note

Pages: 38

3Q22 Commercial Biotech Preview: Regulatory Catalysts Likely The Main Event

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 35.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 78

08/22/2022

Daily Note

Pages: 3

Sparsentan Accepted for Review by EMA in IgAN; EU Approval Expected in 2H23; Affirm Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 5.00

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 79

08/08/2022

Company Report

Pages: 8

2Q Recap: NDA Filing in FSGS Delayed to 2H23; IgAN Remains On Track; Pegtibatinase Granted BTD; Reduce PT to $42

Provider: H.C. Wainwright & Co., Inc.

Analyst: ARCE E

Price: 12.50

Research Provided by a Third Party

Company: Travere Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 80

08/04/2022

Company Report

Pages: 8

Onward For IgAN - Looking Ahead To November PDUFA

Provider: Wedbush Securities Inc.

Analyst: CHICO L

Price: 12.50

Research Provided by a Third Party